Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD)-Reference-Cited by-同舟云学术

Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD)

Published:2018-12-11 Issue:12 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ni Han¹,Moe Soe²,Soe Zay³,Myint Kay Thi⁴,Viswanathan K Neelakantan⁵

Affiliation:

1. SEGi University; Faculty of Medicine; Hospital Sibu, Jalan Ulu Oya Sibu Sarawak Malaysia 96000

2. Melaka Manipal Medical College; Community Medicine; Melaka Melaka Malaysia 75150

3. UCSI University; Internal Medicine; Terengganu Malaysia

4. Faculty of Medicine, SEGi University; Ophthalmology; Sibu Sarawak Malaysia 96000

5. P K Das Institute of Medical Sciences; Department of Internal Medicine; Vaniamkulam, Ottapalam-679522 Kerala India

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011594.pub2/epdf/full

Reference144 articles.

1. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT);Bateman;Respiratory Research,2015

2. Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity;D'Urzo;European Respiratory Journal,2015

3. EUCTR2011-001524-38-GB Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-001524-38-GB

4. The effect of aclidinium/formoterol fixed-dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study;Jones;American Journal of Respiratory and Critical Care Medicine,2014

5. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis;Miravitlles;International Journal of Chronic Obstructive Pulmonary Disease,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bronchodilator therapy in patients with chronic obstructive pulmonary disease: what should be considered in clinical practice when choosing a dosing regimen?;PULMONOLOGIYA;2023-02-10

2. Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations;European Journal of Clinical Pharmacology;2022-12-09

3. A Real-World Study on the Day and Night-Time Symptoms Among Greek COPD Patients Who Recently Initiated Treatment with Dual Bronchodilation: The DANICO Study;International Journal of Chronic Obstructive Pulmonary Disease;2022-09

4. Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study;International Journal of Chronic Obstructive Pulmonary Disease;2022-03

5. Comparison of efficacy and side effects of fixed-dose combination of Aclidinium/Formoterol and Monotherapy of Aclidinium or Formoterol in COPD: A meta-analysis;Heart & Lung;2022-01